ReviewRSC chemical biology2026
Mechanism-based inhibition of zinc-dependent histone deacetylases.
Review in RSC chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The hallmark of a mechanism-based inhibitor is a chemical transformation that occurs upon binding in an enzyme active site that typically yields a more potent inhibitory species. A mechanism-based enzyme inhibitor can be a closely-related analogue of the native substrate, or it can be strikingly different in its structure. Here, the discovery of mechanism-based inhibitors is briefly reviewed to establish a foundation for understanding the mechanism-based inhibition of zinc-dependent histone deacetylases (HDACs), enzymes that play critical roles in epigenetics and the regulation of myriad cellular processes. Notably, the discovery of mechanism-based HDAC inhibition was an unexpected surprise emanating from X-ray crystal structures of enzyme-inhibitor complexes. In each example discussed, the C[double bond, length as m-dash]O, C[double bond, length as m-dash]N, or C[triple bond, length as m-dash]N group of an inhibitor undergoes nucleophilic attack by zinc-bound water in the same manner as the C[double bond, length as m-dash]O group of the native HDAC substrate; however, nucleophilic attack at the bound inhibitor leads to the formation of a tightly-bound enzyme-inhibitor complex. The dual requirements of steric fit as well as fitness for chemical activation can be exploited in unique strategies to enhance inhibitory potency and selectivity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.